Glycanostics

About:

Glycanostics is a biotechnology company that provides a test for the diagnostics of prostate cancer.

Top Investors: European Innovation Council, CB Investment Management

Description:

Glycanostics is a start-up company providing an early-stage cancer diagnostic test. They develop clinically validate and register an affordable, non-invasive next-gen liquid biopsy prostate cancer diagnostic test.

Total Funding Amount:

1.99M EUR

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Bratislava, Bratislava, Slovakia (Slovak Republic)

Founded Date:

2017-01-01

Contact Email:

info(AT)glycanostics.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2021-06-16

IPO Status:

Private

Industries: